Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by Mole101on Jul 18, 2021 4:50pm
138 Views
Post# 33567196

RE:RE:Serology Assay SPR vs Elisa

RE:RE:Serology Assay SPR vs Elisa

  Thanks RC for your insight, if We are talking about two different tests created by two companies, I know BC neuroimmunology has a dedicated work force (14 employees)  testing commercially .PMN has  an unknown number of employees and students working on projects .How will they be able to comercialice the test ones approved?.. 

Ive always been of the opinion that BC neuroscience was doing all the ground work , but I don't have anything to  prove that either way 



=retiredcop]People also have to
keep
in mind that there are 2 separate serology
tests in play here first one is Immusafe test which is basically the work of the Hans frickman lab and a bit of PMN technology.   Then there is the PMN serology test which is almost all their own doing.   Big difference on the percentage of money that will
come into PMN when they are completed and 
[/quote]
 

<< Previous
Bullboard Posts
Next >>